Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy
published in: Journal of Clinical Oncology
date of publication: 2012-01-23
language: English
main subject: peripheral T-cell lymphoma
Cites articles
There is nothing here
Article - wd:Q33399309